Can Indoco Remedies Replicate Its Early Success In Complex Generics Category In U.S.? Nirmal Bang's Take
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Ophthalmic and OTIC suspensions represent a niche complex category in the overall U.S. pharmaceutical market.
We estimate the cumulative market opportunity, represented by products in this category, at $800 million-$1,000 million.
Generic players find it challenging to develop copies of them owing to the complexity in manufacturing process and complex bioequivalence requirements (physiochemical bioequivalence).
The challenges of development get magnified as products in this category are quite small in size which makes it less attractive for the large generic players to invest resources in.
So far, Indoco Remedies Ltd. and Sun Pharmaceutical Industries Ltd. are the only Indian generic manufacturers to have successfully won approvals for generic version of Ophthalmic suspensions in the U.S. market.
Indoco Remedies has recently launched generic version of Azopt (brinozolamide) while Sun Pharma also only recently received approval for gLotemax (loteprednol suspension).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.